Each capsule contains:
Doxycyline monohydrate 100 mg
§ Gonococcal Infections
§ Acute Epididymo-Orchitis
§ Chlamydia trachomatis Infections
§ Nongonococcal Urethritis
§ Inhalational Anthrax (Postexposure).
§ Treatment of the Following Infections Caused by Susceptible Microorganisms:
Rocky Mountain spotted fever
Typhus fever and the typhus group
Respiratory tract infections
Campylobacter fetus infections
Brucellosis (in conjunction w/ streptomycin)
§ Treatment of Infections Caused by the Following Susceptible Strains:
§ Treatment of the Following Infections Caused by Susceptible Microorganisms When Penicillin is Contraindicated:
§ Adjunctive therapy in acute intestinal amebiasis and severe acne
§ It is contraindicated in patients with known hypersensitivity to tetracyclines.
§ May cause permanent discoloration of the teeth (yellow-gray-brown) if used during tooth development (last 1/2 of pregnancy, infancy, and childhood to 8 yrs of age); do not use in this age group, except for anthrax.
Precaution & warnings:
§ Clostridium difficile-associated diarrhea (CDAD) reported; discontinue if CDAD is suspected or confirmed.
§ May decrease fibula growth rate in prematures.
§ May cause an increase in BUN.
§ Photosensitivity, manifested by an exaggerated sunburn reaction, reported; discontinue at the 1st evidence of skin erythema.
§ May result in bacterial resistance if used in the absence of proven or suspected bacterial infection, or a prophylactic indication; take appropriate measures if superinfection develops.
§ Associated with intracranial HTN (pseudotumor cerebri); increased risk in women of childbearing age who are overweight or have a history of intracranial HTN. If visual disturbance occurs, prompt ophthalmologic evaluation is warranted. Intracranial pressure can remain elevated for weeks after drug cessation; monitor patients until they stabilize.
§ Incision and drainage or other surgical procedures should be performed in conjunction with antibacterial therapy when indicated.
§ False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.
Pregnancy & Breastfeeding:
Category D, not for use in nursing.
Dosage and administration:
Adults >8 Years (>45 kg):
Initial: 100mg q12h or 50mg q6h on 1st day
Maint: 100mg qd or 50mg q12h
More Severe Infections (eg, Chronic UTIs): 100mg q12h
Diarrhea, hepatotoxicity, maculopapular/erythematous rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, anorexia, nausea, vomiting, urticaria, serum sickness, pericarditis, hemolytic anemia, thrombocytopenia, neutropenia, eosinophilia.
§ Avoid concomitant use with isotretinoin; may increase risk of intracranial HTN.
§ Depresses plasma prothrombin activity; may require downward adjustment of anticoagulant dose.
§ May interfere with bactericidal action of PCN; avoid concurrent use.
§ Impaired absorption with antacids containing aluminum, Ca2+, or Mg2+, and iron-containing preparations.
§ Decreased T1/2 with barbiturates, carbamazepine, and phenytoin.
§ Fatal renal toxicity reported with methoxyflurane.
§ May render oral contraceptives less effective.
Store below 30°C.
Keep out of reach of children.
USP DI 2009